Study guide

19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

Key Takeaways Explain This Topic AI

The Educate activity area explicitly covers teaching other health professionals and the public, not only patients and families, and includes mentoring colleagues and interpreting the APRN role.

Stigmatizing language measurably changes clinician judgments, so person-first terminology such as person with a substance use disorder and the shift from dirty or clean urine to positive or negative is a clinical intervention rather than etiquette.

Universal, selective and indicated prevention describe interventions aimed at whole populations, at-risk subgroups and individuals already showing early signs.

Effective school-based prevention uses interactive normative-education and resistance-skills approaches; fear-based and information-only programs have repeatedly failed.

Anticipatory guidance means teaching about a foreseeable risk before it occurs, such as overdose risk on release from incarceration or the danger of counterfeit pills for a teenager.

Last updated: September 2026

19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

Quick Answer: Activity Area III names four audiences: patients, families (support systems), other health professionals, and the public. It includes mentoring colleagues (index 8.91), promoting advanced practice nursing by interpreting its role (8.35), anticipatory guidance (9.20), and synthesizing learning, behavior-change and motivational theory when designing health education programs (8.34). Core content: non-stigmatizing language , universal/selective/indicated prevention , interactive rather than fear-based programming , and anticipatory guidance before foreseeable risk events .

1. Language as a Clinical Intervention

Randomized vignette studies have shown that describing the same patient as a "substance abuser" rather than "a person with a substance use disorder" makes clinicians more likely to judge the patient as personally culpable and to endorse punitive rather than therapeutic responses. Language is therefore a measurable determinant of care quality, not a matter of politeness.

Avoid Use

Abuser, addict, junkie, alcoholic (as a clinical label) Person with a substance use disorder; person with alcohol use disorder

  • Dirty / clean urine Positive / negative toxicology, or expected / unexpected result
  • Clean, still using In remission; currently using
  • Habit Substance use disorder
  • Drug of choice Primary substance
  • Substance abuse Substance use, unhealthy use, or substance use disorder

Failed treatment, non-compliant Treatment did not produce the intended result; did not take the medication as prescribed

  • Replacement or substitution therapy Medication for opioid use disorder; treatment
  • Addicted baby, born addicted Infant with neonatal opioid withdrawal syndrome; infant exposed to opioids

Two exceptions worth naming: many people in recovery self-identify as "an alcoholic" or "an addict," and that self-description is their own and should be respected. And in mutual-help settings the language is part of a tradition the APRN does not police. The standard applies to clinical documentation and professional communication .

2. Prevention Frameworks

Level Target Examples

Universal An entire population regardless of risk School curricula for all students; alcohol taxation and minimum unit pricing; limits on outlet density; media campaigns

Selective Subgroups with elevated risk Programs for children of parents with substance use disorders; interventions for justice-involved youth

Indicated Individuals already showing early signs or subthreshold problems Brief intervention for a student after an alcohol-related emergency visit

An older but still-tested framework maps to the same idea: primary prevention (prevent onset), secondary prevention (early detection and intervention, which is where SBIRT sits), and tertiary prevention (limit disability from established disease, where treatment and harm reduction sit).

What works and what does not in school programming

  • Does not work Works
  • Fear-based messaging and scare tactics Interactive skills-based programs with practice and feedback

Information-only lectures Normative education — correcting the near-universal overestimate of how much peers use

  • One-time assemblies with a dramatic speaker Multi-session curricula with booster sessions
  • Zero-tolerance policies that expel users Programs that keep young people connected to school

Normative education is the highest-yield single element. Adolescents dramatically overestimate peer substance use, and correcting that misperception with accurate local data reduces use.

3. Anticipatory Guidance

Anticipatory guidance means delivering information before a predictable risk occurs. High-value examples in addictions nursing:

Predictable event Guidance to deliver in advance

Release from incarceration Tolerance has fallen; overdose risk in the first two weeks is sharply elevated; naloxone and medication must be in place before release, not after

Discharge from residential treatment or hospitalization Same tolerance-loss teaching; schedule the first outpatient contact within days

An adolescent entering high school Counterfeit pills purchased through social media commonly contain fentanyl; one pill can be fatal

A patient starting chronic opioid therapy Storage, disposal, naloxone co-prescription, and the plan for reassessment

A pregnant patient approaching delivery Postpartum relapse risk peaks in the months after birth; plan supports before the baby arrives

A patient with a new prescription for a dopamine agonist Impulse control disorders including gambling can occur; report them without embarrassment

4. Teaching Other Health Professionals

The practice analysis includes mentoring colleagues in acquiring clinical knowledge, skills, abilities and judgement and promoting advanced practice nursing by interpreting its role . Common and high-impact teaching targets:

Emergency department and hospitalist colleagues: initiating buprenorphine in the emergency department is effective and within scope; the X-waiver no longer exists; withdrawal management alone increases overdose death.

Hospital nursing staff: patients on maintenance methadone or buprenorphine still need analgesia for acute pain, and their maintenance dose does not treat pain.

Primary care: low-barrier buprenorphine can be delivered in general practice; a patient does not need to be "ready" to be offered medication.

Obstetric colleagues: medically supervised withdrawal in pregnancy is associated with high relapse rates and is not preferred over maintenance.

Students and new graduates: model non-stigmatizing language explicitly, because it is learned by imitation.

5. Designing a Public Education Program

The practice analysis expects the APRN to synthesize empirical evidence on risk behaviors, learning theories, behavioral change theories, motivational theories and epidemiology when designing programs. A defensible design sequence:

Define the audience and the specific behavior you want to change.

Choose a theory that fits. Health Belief Model for perceived risk and barriers; Theory of Planned Behavior when perceived social norms dominate; Transtheoretical stages when readiness varies widely; Social Cognitive Theory when self-efficacy and modeling matter.

Use local epidemiology , not national statistics, so the audience recognizes itself.

Make it interactive with practice and feedback rather than lecture.

Evaluate readability and comprehensibility of all materials before release.

Measure something — knowledge, intention, naloxone distributed, referrals generated — so the program can be improved. This connects Area III directly to the quality improvement work in Area V.